Seminars in Oncology
Volume 33, Issue 5 , Pages 583-587 , October 2006

Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma—Predictors of Response

  • David F. McDermott

      Affiliations

    • Corresponding Author InformationAddress correspondence to David F. McDermott, MD, Chair, Clinical Research Sub-Committee, DF/HCC Renal Cancer Program, Kirstein Room 153, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA.
    • D.F.M. is a Consultant for Genentech, Bayer, and Onyx, and is on the Speaker’s Bureau for Chiron.
    • ,
  • Michael B. Atkins

      Affiliations

    • M.B.A is a Consultant for Chiron, Schering, Bayer, Onyx, Pfizer, Wyeth, Wilex, Novartis, Genentech, and NovoNordisk, and is on the Speaker’s Bureau for Chiron, Bayer, and Onyx.

References 

  1. Linehan WM, Bates SE, Yang JC. Cancers of the kidney. In:  DeVita VT editors. Cancer: Principles and Practice of Oncology. (ed 7).. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;p. 1139–1167
  2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490
  3. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540
  4. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20:303–314
  5. Pyrhonen S, Salminen E, Lehtonen T, et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma: A phase II study. J Clin Oncol. 1996;15:244;(abstr)
  6. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol. 1987;5:286–291
  7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  8. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patient with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  9. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  10. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant Interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6:S55–S57
  11. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2 (Identification of the antigens mediating response). Ann Surg. 1998;228:307–319
  12. Negrier S, Lasset C, Douillard J-Y, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1272–1278
  13. Yang JC, Sherry RM, Stienberg SM, et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132
  14. Sleijfer DT, Janssen RJ, Buter J, et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on a outpatient basis. J Clin Oncol. 1992;10:1119–1123
  15. McDermott DF, Regan MM, Clark JI, et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–141
  16. Besana C, Borri A, Bucci E, et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon. Eur J Cancer. 1994;9:1292–1298
  17. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863–1874
  18. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3:S92–S97
  19. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer. 2003;98:2566–2575
  20. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996;2:91–94
  21. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988;318:1557–1563
  22. Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapy. J Immunother. 2003;26:394–402
  23. West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898–905
  24. Janik JE, Sznol M, Urba WJ, et al. Erythropoietin production (A potential marker for interleukin-2/interferon-responsive tumors). Cancer. 1993;72:2656–2659
  25. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol. 2000;18:4009–4015
  26. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523–528
  27. Motzer RJ, Bacil J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381
  28. Upton MP, Parker RA, Youmans A, et al. Renal cell carcinoma: Histologic predictors of cytokine response. J Immunother. 2005;28:488–495
  29. Bui MHT, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811
  30. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714–3721
  31. Pantuck AJ, Fang Z, Liu X, et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(16S):386s;(abstr 4535)
  32. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology. 2002;16:4–10

 Supported in part by the DF/HCC Renal Cancer SPORE: P50 CA101942-01.

PII: S0093-7754(06)00270-3

doi: 10.1053/j.seminoncol.2006.06.004

Seminars in Oncology
Volume 33, Issue 5 , Pages 583-587 , October 2006

Article Tools